NCT01934166View on ClinicalTrials.gov

Pharmacokinetic Properties of Nalmefene in Subjects With Renal Impairment and in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

August 31, 2014

Conditions
Renal Impairment
Interventions
DRUG

Nalmefene 18 mg

One single oral dose of 18 mg

Trial Locations (1)

81241

DE801, Munich

All Listed Sponsors
lead

H. Lundbeck A/S

INDUSTRY

NCT01934166 - Pharmacokinetic Properties of Nalmefene in Subjects With Renal Impairment and in Healthy Subjects | Biotech Hunter | Biotech Hunter